Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Markets trade lower after RBI rate hike
Tue, 28 Jan 11:30 am

After opening firm note, the Indian indices are trading below the dotted line in the morning session after the Reserve Bank of India (RBI) hiked he benchmark repo rate by 0.25%. The buying interest is the highest in metal and auto stocks. The selling pressure is the highest in banking and software stocks.

The BSE-Sensex is trading down 40 points and the NSE-Nifty is trading down 18 points. The BSE Mid Cap index is trading up 0.2% and the BSE Small Cap index is trading up 0.3%. The rupee is trading at 62.95 to the US dollar.

Most PSU banks stocks are trading lower today. Bank of India and Canara Bank are among the stocks leading the losses. The Reserve Bank of India (RBI), in its monetary policy today has announced an interest rate hike. It has increased the benchmark lending rate, the repo rate, by 0.25% from 7.75% to 8%. It has left the cash reserve ratio (CRR) unchanged at 4%. RBI governor Raghuram Rajan has pointed to high inflation, especially consumer price inflation as the reason for this decision. However he has also stated that keeping in mind the weak economic growth environment, the RBI might reduce interest rates if inflation levels were to come down.

Most Indian pharma stocks are trading on a positive note. Dishman Pharma and Glenmark Pharma are leading among the stocks leading the gainers. As per a leading business daily, Cadila Healthcare has decided to exit its Japanese business. The company has been operating in Japan through its 100% wholly owned subsidiary. Recently, Cadila undertook a portfolio and business strategy review and the move of exiting Japanese operation was triggered after of the same. The company has been operating in Japan after it acquired 100% stake in Tokyo based Nippon Universal in 2007. It may be noted that all of the company's exports markets grew during 1HFY14 except the Japanese operation which declined by 10.3% YoY. The company's operations are spread across developed countries like US, Europe, Japan and over 25 emerging markets. Cadila Healthcare is trading higher by 0.6% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets trade lower after RBI rate hike". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.